Scientific Progress and Patient-Centered Care at SNO 2026 – Servier Pharmaceuticals
Servier Pharmaceuticals/LinkedIn

Scientific Progress and Patient-Centered Care at SNO 2026 – Servier Pharmaceuticals

Servier Pharmaceuticals shared on LinkedIn:

“The conversations don’t end when the meeting does.

As we wrap up at SNO 2026, we’re energized by the scientific progress shared throughout the meeting and encouraged by the collective commitment to advancing care for people living with brain cancer.

Our teams are carrying this momentum with us and keeping the people living with glioma and their families at the center of our work.”

31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026)

SNO 2026 took place November 12–15 in Philadelphia, Pennsylvania, under the theme ‘Crossing the Translational Divide: From Neurons to Novel Therapies.’

The meeting focused on translating advances in neuroscience into improved diagnosis and treatment of central nervous system (CNS) tumors.

Sessions covered: glioma biology and targeted therapies, immunotherapy, cancer neuroscience, clinical-trial design, brain metastases, neuroimaging, neuropathology, pediatric and rare tumors, radiation, neurosurgery, survivorship, and health disparities.

Clinical updates included the Phase 3 ACTION trial of dordaviprone and a newly initiated Phase 2 study of JZP3507 for recurrent meningioma; GLIX1 Phase 1/2a research in high-grade glioma was also presented.

SNO announced a $75,000 early-career NF1 outcomes-research grant. The central message was to accelerate translation into patient benefit through multidisciplinary collaboration.

You may also be interested in:

Joshua Budhu։ Celebrating the Next Generation of Neuro-Oncology Leaders at SNO 2026

Presenting New Neuro-Oncology Data Across 9 Presentations at SNO 2026 – Servier Pharmaceuticals

Andrew Hide Joins Mark Hughes Foundation Centre for Brain Cancer Research